A steadier glue maker, with deal risk
- The company sells mission-critical glues into packaging, hygiene, construction, electronics, transport, and other industrial markets.
- Fiscal 2025 revenue mix was about 45% HHC, 30% Engineering Adhesives, and 25% Building Adhesive Solutions.
- Q2 2026 looked better than Q1, with total net revenue up 5.8% year over year and sales volume down only 0.4%.
- Engineering Adhesives fell 1.0% organically in Q2, but management said it grew about 5% excluding the solar exit.
- The planned AMS deal would make medical a larger business, but pro forma net leverage is expected near 4x at close.
Better mix, bigger balance-sheet test
H.B. Fuller is trying to become a higher-margin specialty adhesive company, not a plain chemicals supplier. The Q2 2026 update helped that story. Gross margin rose 170 basis points, helped by pricing and restructuring, and the large HHC segment returned to 3.0% organic growth after a weak Q1.
The bull case is that Fuller can use its global reach, lab know-how, and reliable supply to win share in niches where customers care about quality. That showed up in HHC, where management said the company kept serving customers while competitors struggled with petrochemical disruptions.
The planned £715M offer for Advanced Medical Solutions is the big swing. If it closes and works, medical could grow to about 10% of total revenue, adding surgical adhesives, tapes, dressings, sutures, and biosurgical products. These markets should be less tied to short-term consumer demand than some legacy glue uses.
The bear case is still real. Q2 growth improved, but Q1 had a 7.2% sales volume drop. Engineering Adhesives also slipped 1.0% organically in Q2, with automotive down mid-single digits across all regions. The solar exit explains much of the decline, but a weak auto cycle could still hurt one of Fuller's best-margin areas.
Small input, big factory headache
Fuller makes adhesives, sealants, and related specialty chemicals that customers use inside their own products or factory lines. A box, diaper, roof, appliance, circuit board, or car part may use a small amount of glue, but a failure can stop production or damage the finished product.
That is why service matters. Fuller competes on product performance, technical support, quality, price, and supply assurance. Its global footprint helps it serve large multinational customers that want the same product quality across many plants. No single customer is more than 10% of revenue.
The weak point is input cost. Raw materials are mainly petroleum and natural gas derivatives, and they made up about 75% of cost of sales in fiscal 2025. If oil-linked chemicals rise fast or become hard to get, Fuller has to raise prices, reformulate products, or accept lower margins.
The business also has a global currency and demand layer. About 56% of fiscal 2025 net revenue came from outside the United States. That spreads the customer base, but it also adds foreign exchange, local economy, and regulation risk.
Where the glue goes
Hygiene, Health and Consumable Adhesives
This segment sells into packaging, converting, nonwovens, hygiene, health and beauty, flexible packaging, graphic arts, and envelopes. It was the largest fiscal 2025 revenue pool and returned to 3.0% organic growth in Q2 2026.
Engineering Adhesives
These adhesives serve transport, electronics, clean energy, aerospace and defense, textiles, appliances, and heavy machinery. The segment had the highest fiscal 2025 adjusted EBITDA margin at 22.2%, but Q2 2026 was hit by the solar exit and auto weakness.
Building Adhesive Solutions
This segment sells into commercial roofing, heavy infrastructure, building envelope work, woodworking, and insulating glass. It posted 6.2% organic growth in Q2 2026, the fastest of Fuller's three segments that quarter.
Medical adhesives and wound care
The planned AMS acquisition would add surgical adhesives, tapes, dressings, sutures, and biosurgical products. Management wants medical to become about 10% of total revenue after the deal.
Technical service and formulation support
Fuller does not only sell a chemical. It helps customers pick, test, and use the right adhesive, which can make switching suppliers harder when the product is built into a factory process.
Three segments after the reset
Shares use fiscal 2025 net revenue after Fuller realigned into HHC, Engineering Adhesives, and Building Adhesive Solutions. No single customer was more than 10% of revenue, but about 56% of net revenue came from outside the United States.
What could break the story
Petrochemical cost squeeze
High impact · Medium oddsRaw materials made up about 75% of cost of sales in fiscal 2025, and many are tied to petroleum or natural gas. If costs rise faster than Fuller can raise prices, gross margin could fall. Supply shortages can also push customers to test other suppliers.
AMS integration and debt paydown
High impact · Medium oddsThe AMS deal would move Fuller into a more attractive medical mix, but it also adds execution risk. Management expects pro forma net leverage of about 4x at close and says it can return to a 2.5x to 3.0x target range within two years. A downturn or weak deal synergies could slow that path.
Consumer volume relapse
Medium impact · Medium oddsHHC improved in Q2 2026, but Q1 showed how quickly volumes can weaken. If consumers buy fewer packaged, hygiene, or health and beauty products, customer orders can slow. That would pressure Fuller's largest revenue segment.
Automotive cycle drag
Medium impact · Medium oddsEngineering Adhesives is a key profit engine, but management said automotive was down mid-single digits in all three regions in Q2 2026. High interest rates or weaker auto production could keep that pressure in place. The solar exit also makes clean reads harder until comparisons normalize.
Project ONE uncertainty
Medium impact · Low oddsFuller's Project ONE ERP system was not a major focus in the latest update, leaving timing and remaining cost less clear. ERP projects can disrupt orders, billing, and factory planning if rollout goes poorly. The risk is not proven, but it is worth tracking.
In one breath
What does H.B. Fuller actually make?
H.B. Fuller makes adhesives, sealants, and other specialty chemicals. Its products are used in packaging, hygiene goods, construction, electronics, transport, roofing, and many factory processes.
Why does the AMS acquisition matter?
AMS would add medical products such as surgical adhesives, tapes, dressings, sutures, and biosurgical materials. Fuller says the deal would make medical about 10% of total revenue, but it would also push net leverage near 4x at close.
Is the Engineering Adhesives decline a major warning sign?
It is a warning sign to watch, but not a clean break in the story. Q2 organic revenue fell 1.0%, yet management said the segment grew about 5% excluding the lower-margin solar business exit, while automotive weakness was the other main drag.
What is the biggest cost risk for Fuller?
Raw materials are the main cost risk. They made up about 75% of fiscal 2025 cost of sales, and many are based on petroleum or natural gas, so price spikes or shortages can hurt margins.